An estimated 10 to 13% of women of reproductive age worldwide have polycystic ovary syndrome, making it one of the most common hormonal conditions on the planet. In raw numbers, that translates to roughly 1 in 10 women globally. In the United States alone, PCOS affects as many as 5 million women. Perhaps most striking: up to 70% of those who have it don’t know it yet.
The Global Numbers
The World Health Organization estimates that PCOS affects 10 to 13% of women globally. That range exists partly because the condition looks different across populations and partly because of how it’s diagnosed, but even the low end makes PCOS the most common endocrine disorder in women of reproductive age. It’s also the leading cause of ovulatory dysfunction: up to 80% of women who don’t ovulate regularly have PCOS.
Reported rates vary dramatically by country. Japan has the highest recorded incidence at about 413 new cases per 100,000 women per year, followed by New Zealand at 255 and Brunei at 242. At the other end of the spectrum, several Central and Southeastern European countries report rates below 10 per 100,000, with Bosnia and Herzegovina and Albania at the bottom. Some of these differences reflect genuine variation in genetics and lifestyle factors, but much of the gap comes down to how aggressively different healthcare systems screen for and diagnose the condition.
Why the Numbers Depend on Which Criteria You Use
One reason PCOS statistics can be confusing is that doctors don’t all use the same checklist to diagnose it. The three main diagnostic frameworks produce wildly different numbers when applied to the same group of women. In one study that compared all three criteria in the same population, the strictest set (the NIH criteria from 1990, which requires both irregular periods and elevated androgens) identified about 26% of women as having PCOS. A slightly broader set captured 29%. But the most widely used framework today, called the Rotterdam criteria, diagnosed 63% of the same group. Rotterdam requires only two of three features: irregular periods, elevated androgens, or ovarian cysts on ultrasound. That flexibility captures more women but also explains why prevalence estimates can swing so widely depending on the source.
Rates by Ethnicity
PCOS doesn’t affect all ethnic groups equally. A large study of over 400,000 women in the U.S. receiving outpatient care found that South Asian women had the highest diagnosed prevalence at 3.5%, more than double the rate seen in Chinese women (1.1%). Hispanic women came in at 1.9%, Black women at 1.7%, Filipino women at 1.7%, and white women at 1.6%.
These numbers reflect diagnosed cases only, which means they capture who’s getting identified in the healthcare system rather than who actually has the condition. The true rates are almost certainly higher across every group. Still, the more than twofold difference among Asian subgroups alone highlights that PCOS risk has a strong genetic and metabolic component that varies across populations.
PCOS in Teenagers
The condition doesn’t wait until adulthood. An estimated 3 to 11% of adolescent girls have PCOS, though diagnosing it in teenagers is tricky because irregular periods and acne are common during puberty regardless. Studies from different countries illustrate this range: about 4% of tenth-grade girls in one Chinese study, roughly 7% of adolescent girls in a South Indian study, and varying rates in Iranian teenagers depending on which diagnostic criteria were applied (as low as 0.7% with the strictest framework, up to 4.2% with Rotterdam).
The Undiagnosed Majority
The most important number in PCOS statistics may be this one: up to 70% of women with the condition worldwide remain undiagnosed. That means for every woman who knows she has PCOS, roughly two more are living with it without answers. Several factors drive this gap. Symptoms like irregular periods, weight gain, and acne are often dismissed or attributed to stress. Many women don’t realize that thinning hair, dark skin patches, or difficulty losing weight could all point to a single underlying condition. And healthcare providers sometimes don’t screen for PCOS unless a woman is actively trying to get pregnant and struggling.
This diagnostic delay has real consequences. PCOS is closely linked to insulin resistance, which over time raises the risk of type 2 diabetes, heart disease, and stroke. Women who don’t know they have PCOS miss the window for early lifestyle changes and monitoring that can reduce those long-term risks.
The Financial Toll
PCOS carries a significant economic burden, particularly in the United States. Diagnosing and treating the condition cost an estimated $8 billion nationwide in 2020. That figure includes $3.7 billion for reproductive complications like infertility treatment and $4.3 billion for long-term metabolic conditions such as diabetes and cardiovascular problems. Pregnancy complications, including gestational diabetes and preeclampsia, accounted for about 5% of total costs. The diagnostic process itself was less than 2% of the overall spending, meaning the vast majority of the financial burden comes from managing the downstream health effects of PCOS over a woman’s lifetime.
Where Rates Are Climbing Fastest
PCOS incidence is rising in many parts of the world, but the steepest increases between 1990 and 2019 occurred in sub-Saharan Africa and parts of the Middle East. Equatorial Guinea saw the fastest-growing incidence rate, followed by Angola and Benin. For the overall health burden of PCOS, Qatar and the United Arab Emirates showed some of the sharpest increases. These trends likely reflect a combination of rising obesity rates, greater urbanization, dietary shifts toward processed foods, and, in some cases, improved detection as healthcare infrastructure expands.